The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVenture Life Regulatory News (VLG)

Share Price Information for Venture Life (VLG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 39.00
Bid: 38.50
Ask: 39.50
Change: 0.00 (0.00%)
Spread: 1.00 (2.597%)
Open: 39.00
High: 38.70
Low: 38.70
Prev. Close: 39.00
VLG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

New distribution agreements signed

25 Jun 2014 07:00

RNS Number : 4460K
Venture Life Group PLC
25 June 2014
 



 

Venture Life Group plc

("Venture Life" or "the Group")

New distribution agreements signed with two partners

 

Bracknell, UK - 25 June 2014: Venture Life Group plc (AIM: VLG), the international consumer self-care group focused on developing, manufacturing and commercialising products for the ageing population, announces that it has signed new long-term distribution agreements with two distribution partners. The agreements cover the distribution of four Venture Life products in three territories:

 

· NeuroAge™ NRG and NeuroAge™ Sleep signed with an existing partner in Romania and Moldova;

· ZipClear™ signed with a new partner in Turkey; and

· Calm-eze™ signed with a new partner in Turkey.

 

Following the recent completion of development by the Group of NeuroAge™ NRG and NeuroAge™ Sleep - two new line extensions for the NeuroAge™ range - a new long-term distribution agreement has been signed with MedMen for these products. MedMen already owns distribution rights for NeuroAge™ in Romania and Moldova and has now acquired the rights for NeuroAge™ NRG and NeuroAge™ Sleep for distribution, also in Romania and Moldova.

 

The acquisition of the rights to these two line extensions confirms the initial success of the market launch of NeuroAge™ in 2013 and the market launch by MedMen of the first line extension is expected in Q1 2015.

 

Distribution agreements have also been signed for ZipClear™ and Calm-eze™ with GM-BAY, a fast-growing and ambitious distribution company, for these products to be distributed in Turkey, and market launch is expected in Q1 2015, following registration. Following the successful first commercialisation of Procto-eze™, Immobilice™, and Guma-eze™, announced on 23 April 2014, the commercialisation of ZipClear™ is further evidence of tangible synergies arising from the Biokosmes acquisition, which completed earlier in 2014.

Jerry Randall, Chief Executive Officer of Venture Life, commented:

"We are delighted that one of our existing distribution partners has signed a further distribution agreement for new line extensions from our expanding pipeline so soon after the completion of development. We believe that this is an endorsement of our product development strategy and reflects the success of the market launch of the NeuroAge™ brand in late 2013. The new distribution agreement for ZipClear™, a product that was originally developed by Biokosmes, demonstrates further benefits from our recent acquisition. Venture Life continues to grow the commercial partner base for its products and will continue to commercialise products from the Biokosmes portfolio, in line with its stated strategy."

 

- Ends -

 

For further information please contact:

Venture Life Group PLC

Jerry Randall, Chief Executive Officer

James Hunter, Chief Financial Officer +44 (0) 1344 742870

 

Square1 Consulting

David Bick

Mark Longson +44 (0) 20 7929 5599

 

JW Communications

Julia Wilson +44 (0) 7818 430877

 

 

Notes to editors

 

About Venture Life

Venture Life is an international consumer self-care company focused on developing, manufacturing and commercializing products for the ageing population. The Group's product range and pipeline currently include food supplements for lowering cholesterol and maintaining brain function, dermo-cosmetics for addressing the signs of ageing, and medical devices for improving minor aches and pains, dry eyes and itchy skin. The products, which typically are recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies supplied by the Group's international distribution partners.

 

Through its manufacturing company, Biokosmes, the Group also provides development and manufacturing services to companies in the medical device and cosmetic sectors.

The Group's own branded products are currently sold or partnered in over 40 countries and currently include:

· food supplements to maintain brain function and memory;

· dermo-cosmetics for addressing the signs of skin ageing and hair loss, and

· medical devices for improving conditions such as minor aches and pains, dry eyes and itchy skin.

 

The Company has a healthy development pipeline including products in areas such as diabetes, cardiovascular health, obesity, cognitive function and skin ageing. Products coming from the pipeline will be expected to have intellectual property protection and be supported by independent clinical evidence of efficacy.

 

About NeuroAge™

NeuroAge™ is a food supplement formulated to help support alertness, cognitive function and mental performance in a healthy brain. The key components have been extensively studied and these studies show their action in supporting cognitive function.

 

About NeuroAge™ NRG and NeuroAge™ Sleep

NeuroAge™ NRG and NeuroAge™ Sleep are new additions to the NeuroAge™ range. As well as supporting cognitive function, NeuroAge™ NRG has been specially formulated to maintain alertness and NeuroAge™ Sleep helps to promote sleep and reduce the time taken to fall asleep. 

 

About ZipClear™

ZipClear™ helps to relieve symptoms associated with herpes simplex virus type 1 (otherwise called cold sores) commonly appearing around the mouth and lip area. ZipClear™ creates an invisible barrier to protect and soothe against symptoms of irritation and burning sensations. It helps to prevent the virus from spreading and helps keep the affected area clean.

 

About Calm-eze™

Calm-eze™ is indicated for the rapid relief of dry, itchy skin, a common problem amongst the ageing population. It is a non-greasy emollient expertly formulated with a triple action effect to cool, soothe and calm itchy skin, as well as to keep it hydrated.

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAQKQDBFBKDPAB
Date   Source Headline
8th Jan 20187:00 amRNSEuropean Business Awards 'Ones to Watch List'
24th Nov 20177:00 amRNSNew exclusive partner secured in Austrian market
23rd Nov 201711:14 amRNSUK Bond Network presentation
14th Nov 20177:00 amRNSVox Markets
30th Oct 20177:00 amRNSUltraDEX update
10th Oct 20177:00 amRNSHolding(s) in Company
2nd Oct 20177:00 amRNSFDA approval for the US market
21st Sep 20177:00 amRNSHalf-year Report
7th Sep 20177:00 amRNSDistribution partners and Lubatti China update
4th Sep 20177:00 amRNSNotice of Results
7th Aug 20174:24 pmRNSDirector/PDMR Shareholding
19th Jul 20177:00 amRNSDistribution partner for UltraDEX & patent update
12th Jul 20177:00 amRNSTrading update
23rd May 201710:59 amRNSResult of AGM
23rd May 20177:00 amRNSUltraDEX Patent Grants and Distribution Update
18th May 20177:00 amRNSTwo new CE Mark approvals
10th May 20179:00 amRNS'1000 Companies to Inspire Britain' 2017 report
4th May 20177:00 amRNSChange of Adviser
4th May 20177:00 amRNSGrant of Options
25th Apr 20177:00 amRNS2017 Long Term Incentive Plan and Grant of Options
29th Mar 20173:36 pmRNSUK Investor Show attendance
23rd Mar 20177:00 amRNSFinal Results
1st Mar 20177:00 amRNSDirectorate Change
1st Feb 20171:08 pmRNSHolding(s) in Company
31st Jan 20174:39 pmRNSInvestor Day presentation now available
26th Jan 20177:00 amRNSTrading update
20th Dec 20167:00 amRNSInvestor evening
29th Nov 20166:06 pmRNSHolding(s) in Company
28th Nov 20167:00 amRNSAppointment of Vox Markets
17th Nov 20167:00 amRNSInvestor evening
14th Nov 20167:00 amRNSTrading update
10th Nov 20167:00 amRNSDirectorate Change
10th Oct 20167:00 amRNSUltraDEX advertising launch
7th Oct 201612:10 pmRNSIssue of Equity
29th Sep 20167:00 amRNS2016 LTIP adopted & Grant of Options
21st Sep 20167:00 amRNSHalf-year Report
21st Sep 20167:00 amRNSAppointment of joint broker
7th Sep 20167:00 amRNSNotice of Results
29th Jul 20167:00 amRNSPre-close trading statement
22nd Jun 201612:35 pmRNSResult of AGM
14th Jun 201612:18 pmRNSDirector/PDMR Shareholding
17th May 20164:17 pmRNSDirector/PDMR Shareholding
9th May 20161:13 pmRNSDirector/PDMR Shareholding
9th May 20167:00 amRNSAnnual Financial Report
4th May 20167:00 amRNSFinal Results
3rd May 20167:00 amRNSFirst distribution agreements signed for UltraDEX
31st Mar 20167:00 amRNSDistribution Deals on Benecol 'once a day' Sachet
29th Mar 20167:02 amRNSNotice of Results
18th Mar 201611:04 amRNS'1000 Companies to Inspire Britain 2016' report
7th Mar 20167:00 amRNSCompletion of Acquisition

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.